The analysis demonstrated the significant prognostic value of SPACA6P-AS expression levels across various clinicopathological feature subgroups, including N stage-N0, M stage-M0, pathological stage II, progesterone receptor (PR) positive, Caucasian race, age over 60, invasive ductal carcinoma, no radiation therapy, Estrogen Receptor (ER) positive, Human Epidermal Growth Factor Receptor 2 (HER2) negative, PAM50-LumA subtype, postmenopausal status, and anatomical tumor subdivision (Fig. 5). This evidence concerns the gene ESR1 and neoplasm.